Nomad Power Solutions

Nomad Power Solutions

Electrical Equipment
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

$58M

Market Cap • 9/28/2026

2005

(21 years)

Founded

2007

(19 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

2,3

P/S

17,2

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,6

EPS

—

Market Cap

Market Cap

58M

EV

47,5M

EV/Revenue

14,1

EV/EBITDA

-4,9

EV/EBIT

-4,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-62,2M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

50,6%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

27,6%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

10,1%

CAGR Net Income 5Y

13,5%

CAGR EPS 5Y

-27,1%

CAGR OCF 5Y

-11,1%

Leverage

N.D./EBITDA

1,2

Debt/Equity

0%

Current Ratio

12,9

Quick Ratio

12,8

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium